OncoSil Medical (ASX:OSL) reveals results of a study showing that the addition of OncoSil™ to systemic chemotherapy significantly increases the vascularity of the primary pancreatic tumors and at the same time results in a significant decrease in the size of the tumours. - This is believed to be the first study in humans demonstrating that the poor vascularity of pancreatic cancer tumors can be increased - This may consequently increase the concentration of chemotherapy agents within the tumor ...
$OncoSil Medical Ltd(OSL.AU)$is making strategic moves! Their new share offering application could be a great opportunity for the company to raise capital and fuel further success.
OncoSil Medical Ltdに関するコメント
- This is believed to be the first study in humans demonstrating that the poor vascularity of pancreatic cancer tumors can be increased
- This may consequently increase the concentration of chemotherapy agents within the tumor ...
まだコメントはありません